Regarding the comparison between potent P2Y12 inhibitors, the ISAR-REACT 5 trial compared prasugrel plus aspirin vs. ticagrelor plus aspirin in ACS patients, and demonstrated that treatment with prasugrel, compared to ticagrelor, significantly reduced the composite rate of death, MI, or stroke (6.9% vs. 9.3%, p = 0.006) without any increase in bleeding complications (4.8% vs. 5.4%, p = 0.46) [55]. This evidence concerns the gene P2RY12 and stroke disorder.